A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2018
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2018 Planned initiation date changed from 11 Jul 2018 to 10 May 2019.
- 16 Jul 2018 Planned number of patients changed from 480 to 600.